Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Open accessThe DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Abstract
Glioblastoma multiforme (GBM) is a highly aggressive form of brain cancer that is difficult to treat due to its resistance to both radiation and chemotherapy. This resistance is largely due to the unique biology of GBM cells, which can evade the effects of conventional treatments through mechanisms such as increased resistance to cell death and rapid regeneration of cancerous cells. Additionally, the blood–brain barrier makes it difficult for chemotherapy drugs to reach GBM cells, leading to reduced effectiveness. Despite these challenges, there are several treatment options available for GBM. The standard of care for newly diagnosed GBM patients involves surgical resection followed by concurrent chemoradiotherapy and adjuvant chemotherapy. Emerging treatments include immunotherapy, such as checkpoint inhibitors, and targeted therapies, such as bevacizumab, that attempt to attack specific vulnerabilities in GBM cells. Another promising approach is the use of tumor-treating fields, a type of electric field therapy that has been shown to slow the growth of GBM cells. Clinical trials are ongoing to evaluate the safety and efficacy of these and other innovative treatments for GBM, intending to improve with outcomes for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Soler, D. C., Kerstetter-Fogle, A. E., McCormick, T. S., & Sloan, A. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-021-03902-8 · Cited by 15
Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach
D’Alessandris, Q. G., Martini, M., Cenci, T., Bonaventura, R. D., Lauretti, L., Stumpo, V., Olivi, A., Larocca, L. M., Pallini, R., & Montano, N. (2022) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.20.04943-7 · Cited by 12
Haddad, A. F., Young, J. S., Mummaneni, N. V., Kasahara, N., & Aghi, M. K. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03684-5 · Cited by 12
Molecularly Targeted Clinical Trials
Smith-Cohn, M., Celiku, O., & Gilbert, M. R. (2021) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2020.12.002 · Cited by 12
Current Considerations in the Treatment of Grade 3 Gliomas
Jo, J., & Schiff, D. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01000-z · Cited by 11
Kochar, A., Madhavan, M., Manjila, S. V., Scoco, A. N., Belle, V., & Geertman, R. T. (2018) · Asian Journal of Neurosurgery · doi:10.4103/ajns.ajns_266_16 · Cited by 9
Sahoo, R. K., Gupta, T., Batheja, S., Goyal, A. K., & Gupta, U. D. (2022) · Current Drug Metabolism · doi:10.2174/1389200223666220616125524 · Cited by 8
Cerebrospinal fluid–suppressed T2‐weighted MR imaging at 7 T for human brain
Pan, J. W., Moon, C., & Hetherington, H. P. (2018) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27598 · Cited by 7
Zeng, Y., & Chen, X. (2021) · Aging · doi:10.18632/aging.202645 · Cited by 5
(2003) · PubMed
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Immunogenic cell death mediated TLR3/4-activated MSCs in U87 GBM cell line
Emami Meybodi, S. M., Moradi Moraddahande, F., & Dehghani Firoozabadi, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29858 · Cited by 3
“Several mechanisms of action have been mentioned for glioma resistance, as well as DNA-repair enzymes, mismatch-repair (MMR) complex formation, glioma initiating cells (GICs), and tumour hypoxia that support tumour recurrences, progression, and therapeutic resistance [4].”
Background
Metadata
- Authors
- Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-04-01
- Volume
- 15
- Issue
- 7
- Pages
- 2116
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4362584099
- Cited by
- 293
- References
- 210
- FWCI
- 41.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.